Stock Scorecard



Stock Summary for Becton Dickinson & Company (BDX) - $177.84 as of 11/7/2025 7:30:54 PM EST

Total Score

13 out of 30

Safety Score

61 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BDX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BDX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BDX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BDX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BDX (61 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 4
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 5
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BDX

Hologic's Breast Health Rebounds, Takes Spotlight in Buyout Deal 11/7/2025 12:37:00 PM
Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal - Becton Dickinson ( NYSE:BDX ) 11/6/2025 6:11:00 PM
BD Stock Slips in Pre-Market Despite Q4 Earnings Beat, Margins Up 11/6/2025 5:58:00 PM
Becton Dickinson ( BDX ) Tops Q4 Earnings and Revenue Estimates 11/6/2025 12:40:00 PM
McKesson ( MCK ) Surpasses Q2 Earnings Estimates 11/5/2025 10:25:00 PM
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings? 11/3/2025 5:00:00 PM
Merit Medical ( MMSI ) Q3 Earnings and Revenues Surpass Estimates 10/30/2025 10:20:00 PM
Global Surgical Instrument Tracking Systems Market to Reach USD 751.2 Million by 2030 | MarketsandMarkets™ 10/30/2025 2:30:00 PM
Here's Why Becton Dickinson ( BDX ) is a Strong Growth Stock 10/23/2025 1:45:00 PM
BDX Launches AI-Enabled Platform to Unify Healthcare Connectivity 10/21/2025 11:41:00 AM

Financial Details for BDX

Company Overview

Ticker BDX
Company Name Becton Dickinson & Company
Country USA
Description Becton, Dickinson and Company (BDX) is a leading American multinational medical technology company renowned for its development and production of critical medical devices, instrument systems, and reagents that significantly improve global healthcare outcomes. With a diversified portfolio that supports a wide array of diagnostic and therapeutic procedures, BDX effectively addresses the evolving needs of the healthcare community while providing analytical and consulting services to enhance its operational footprint. Driven by a robust commitment to innovation, underscored by considerable investments in research and development, BDX is poised to capitalize on emerging trends in the medical technology sector, solidifying its position as a key player in advancing healthcare solutions.
Sector Name HEALTHCARE
Industry Name MEDICAL INSTRUMENTS & SUPPLIES
Most Recent Quarter 6/30/2025
Next Earnings Date 2/3/2026

Stock Price History

Last Day Price 177.84
Price 4 Years Ago 230.76
Last Day Price Updated 11/7/2025 7:30:54 PM EST
Last Day Volume 2,936,519
Average Daily Volume 2,082,736
52-Week High 248.00
52-Week Low 161.47
Last Price to 52 Week Low 10.14%

Valuation Measures

Trailing PE 32.49
Industry PE 662.72
Sector PE 107.44
5-Year Average PE 17.17
Free Cash Flow Ratio 69.47
Industry Free Cash Flow Ratio 40.15
Sector Free Cash Flow Ratio 27.89
Current Ratio Most Recent Quarter 1.10
Total Cash Per Share 2.56
Book Value Per Share Most Recent Quarter 88.87
Price to Book Ratio 2.16
Industry Price to Book Ratio 3.47
Sector Price to Book Ratio 33.18
Price to Sales Ratio Twelve Trailing Months 2.38
Industry Price to Sales Ratio Twelve Trailing Months 47.23
Sector Price to Sales Ratio Twelve Trailing Months 16.85
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 286,627,000
Market Capitalization 50,973,745,680
Institutional Ownership 93.23%

Dividends

Ex-Dividend Date 12/8/2025
Previous Dividend Amount 1.0400
Current Dividend Amount 1.0500
Total Years Dividend Increasing Dividend Aristocrat - Increasing for 40 Years
Trailing Annual Dividend Rate 4.16
Trailing Annual Dividend Yield 2.34%
Forward Annual Dividend Rate 4.20
Forward Annual Dividend Yield 2.36%
5-Year Dividend Payments Count 21
3-Year Average Dividend Yield 1.65%
5-Year Average Dividend Yield 1.55%
1-Year Dividend Growth Rate Percentage 7.20%
3-Year Dividend Growth Rate Percentage 6.45%
5-Year Dividend Growth Rate Percentage 5.55%
All-Time Dividend Growth Rate Percentage 10.49%
Dividend Payout Ratio 76.19%

Income Statement

Quarterly Earnings Growth YOY 19.00%
Annual Earnings Growth 14.89%
Reported EPS 12 Trailing Months 5.46
Reported EPS Past Year 14.42
Reported EPS Prior Year 13.16
Net Income Twelve Trailing Months 1,606,000,000
Net Income Past Year 1,705,000,000
Net Income Prior Year 1,484,000,000
Quarterly Revenue Growth YOY 10.40%
5-Year Revenue Growth 3.14%
Operating Margin Twelve Trailing Months 17.80%

Balance Sheet

Total Cash Most Recent Quarter 735,000,000
Total Cash Past Year 1,717,000,000
Total Cash Prior Year 1,416,000,000
Net Cash Position Most Recent Quarter -16,796,000,000
Net Cash Position Past Year -16,223,000,000
Long Term Debt Past Year 17,940,000,000
Long Term Debt Prior Year 14,738,000,000
Total Debt Most Recent Quarter 17,531,000,000
Equity to Debt Ratio Past Year 0.59
Equity to Debt Ratio Most Recent Quarter 0.59
Total Stockholder Equity Past Year 25,889,000,000
Total Stockholder Equity Prior Year 25,797,000,000
Total Stockholder Equity Most Recent Quarter 25,473,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 2,550,000,000
Free Cash Flow Per Share Twelve Trailing Months 8.90
Free Cash Flow Past Year 3,073,000,000
Free Cash Flow Prior Year 2,115,000,000

Options

Put/Call Ratio 3.09
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -3.75
MACD Signal -2.30
20-Day Bollinger Lower Band 169.47
20-Day Bollinger Middle Band 184.86
20-Day Bollinger Upper Band 200.24
Beta 0.28
RSI 43.26
50-Day SMA 199.41
150-Day SMA 225.07
200-Day SMA 227.66

System

Modified 11/7/2025 6:32:47 PM EST